The Road To University Technology Licensing Is Littered With Patents That Languish

Despite well-publicized, lucrative licensing deals, most university technology experts find that patenting and licensing inventions is a process laden with potential pitfalls. While universities claim that the investment is generally worthwhile for a number of reasons, the challenge, many specialists say, is choosing the right project and matching it with the right industry at the right time. Patents often languish, investments frequently sour. The fact is, for every income-earning patent, mil

Written bySteven Benowitz
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

The fact is, for every income-earning patent, million-dollar winners aside, there are probably three or four losers -- patented research in which companies, for one reason or another, simply aren't interested. University licensing specialists claim that with patenting costs that can run tens of thousands of dollars, they are often content to break even.

"If your goal is to make millions, there are probably less risky ways than trying to commercialize university research results," notes Teri Willey, director of special technology projects in Purdue University's Office of Technology Transfer. Purdue sees a return on its investment in only 10 percent of its patents.

"Most patents never make a nickel," confirms Walter Haessler, president of Cornell Research Foundation Inc., a wholly owned subsidiary of Cornell University charged with marketing Cornell-based technologies. "Universities aren't in this to make money," he contends. "Only a few make big money.

SEEKING STARS: Howard Califano at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies